CAJ | 학술논문

目前全人源TRAIL受体（ TRAIL-Rs）的单克隆抗体（单抗）对肿瘤靶向治疗已进入临床Ⅰ～Ⅳ期研究。 TRAIL-Rs单抗可分别与死亡受体TRAIL-R1和TRAIL-R2结合，形成死亡诱导信号复合体（ DISC），诱导肿瘤细胞凋亡，成为抗肿瘤抗体药物研发的热点之一。全人源TRAIL-Rs单抗与放疗、化疗药物或其它制剂以及免疫治疗方法联合应用在肿瘤治疗中取得了显著的效果，为临床抗肿瘤治疗提供了新方案。
목전전인원TRAIL수체（ TRAIL-Rs）적단극륭항체（단항）대종류파향치료이진입림상Ⅰ～Ⅳ기연구。 TRAIL-Rs단항가분별여사망수체TRAIL-R1화TRAIL-R2결합，형성사망유도신호복합체（ DISC），유도종류세포조망，성위항종류항체약물연발적열점지일。전인원TRAIL-Rs단항여방료、화료약물혹기타제제이급면역치료방법연합응용재종류치료중취득료현저적효과，위림상항종류치료제공료신방안。
Monoclonal antibodies(mAbs)to human TRAIL receptors(TRAIL-Rs)have been developed in tumor targeted therapy and currently used in clinical Ⅰ~Ⅳtrials.MAbs can bind death-receptors(TRAIL-R1 and TRAIL-R2)and then results in formation of the death inducing signaling complex (DISC)and apoptosis of tumor cells.TRAIL -Rs mAbs have become one of the research and development hotspots of anti -tumor drugs.These mAbs have achieved remarkable results in combination with radio -or chemo-therapy drugs or oth-er agents and immunotherapy in the treatment of tumor and offer a new therapeutic strategy for clinical tumor treatment.